Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
BofA Securities Upgrades Amylyx Pharmaceuticals(AMLX.US) to Buy Rating, Announces Target Price $10
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Neutral Stance on Amylyx Pharmaceuticals Amid Promising Data and Uncertainties
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Leerink Partners Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $4